age at diagnosis was 49.5 years (range, 28.8–77.3 years). The most common NAC regimen was doxorubicin/cyclophosphamide/paclitaxel (AC-T; n=62; 40.5%). Patients receiving epirubicin/paclitaxel (ET) were part of an institutional phase II trial. 11
Search Results
Predictors of Locoregional Recurrence After Failure to Achieve Pathologic Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Prashant Gabani, Emily Merfeld, Amar J. Srivastava, Ashley A. Weiner, Laura L. Ochoa, Dan Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michael J. Naughton, Cynthia Ma, and Imran Zoberi
Local Treatment of Malignant Brain Tumors Using Implantable Chemotherapeutic Polymers
Gary L. Gallia, Steven Brem, and Henry Brem
biocompatibility of a biodegradable, controlled-release polymer in rats . J Biomed Mater Res 1989 ; 23 : 253 – 266 . 10 Fung LK Ewend MG Sills A . Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel
Resurrection of PARP Inhibitors in Breast Cancer
Tomas G. Lyons and Mark E. Robson
study of single-agent veliparib showed a PFS of 5.2 months, with a response rate of 14% and 36% for patients with BRCA1 and BRCA2 mutations, respectively. 25 Results of combining veliparib with carboplatin and paclitaxel in the randomized phase II
Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer
Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris
chemotherapy agents, including bleomycin, carboplatin, cisplatin, docetaxel, doxorubicin, and paclitaxel, used in various combinations, have been reported to have palliative benefit in small nonrandomized trials, but little impact on survival. 1 , 3 , 4 As a
Breast Cancer, Version 3.2013
Richard L. Theriault, Robert W. Carlson, Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar
together with other active cytotoxics, such as paclitaxel and vinorelbine 14 , 15 ( ClinicalTrials.gov identifier: NCT01276041). Phase III trials of pertuzumab plus chemotherapy without trastuzumab have not been reported. Pertuzumab has antitumor
Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature
Saranya Chumsri, Ethan S. Sokol, Aixa E. Soyano-Muller, Ricardo D. Parrondo, Gina A. Reynolds, Aziza Nassar, and E. Aubrey Thompson
doxorubicin and cyclophosphamide every 2 weeks for 4 cycles followed by weekly paclitaxel for 12 weeks. Follow-up CT of the chest, abdomen, and pelvis after neoadjuvant chemotherapy showed a partial response with no evidence of distant metastases. The patient
Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis
Eric T. Wong, Shiva Gautam, Christopher Malchow, Melody Lun, Edward Pan, and Steven Brem
significant. 11 In metastatic non–small cell lung cancer, the benefit of bevacizumab at 15 mg/kg every 3 weeks was only slightly higher than at a lower dose of 7.5 mg/kg when both drugs were combined with carboplatin and paclitaxel. 12 The higher bevacizumab
First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition
Victor T.G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada, and Eddy S. Yang
benefit to treatment with combined carboplatin and paclitaxel. 6 Notably, this cohort of 18 patients was established from a retrospective review of >8 years of clinical records, which exemplifies the difficulty of performing robust prospective clinical
NCCN Guidelines Updates: Breast Cancer
Melinda L. Telli, William J. Gradishar, and John H. Ward
well. In IMpassion130, patients with triple-negative breast cancer were randomized to receive albumen-bound (nab) paclitaxel alone or with atezolizumab in the first-line setting. Among PD-L1–positive patients, progression-free survival improved from 5
Thymic Malignancies*
David S. Ettinger, Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Ramaswamy Govindan, Frederic W. Grannis Jr., Thierry Jahan, David H. Johnson, Anne Kessinger, Ritsuko Komaki, Feng-Ming Kong, Mark G. Kris, Lee M. Krug, Quynh-Thu Le, Inga T. Lennes, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, and Stephen C. Yang
treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone . J Thorac Oncol 2007 ; 2 : 73 – 78 . 31. Lemma GL Loehrer PJ Sr Lee JW . A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic
